Feature DURECT awaiting Pfizer meeting with FDA on Remoxy By Len Zehr DURECT (NASDAQ:DRRX) has a lot riding on a meeting in late March between its marketing partner, Pfizer, and the FDA to discuss resubmitting a new drug application for its lead pain drug, Remoxy, as a tamper... February 26, 2013